Neurotrophic factors regulate the survival and growth of neurons, and influence synaptic efficiency and plasticity. Several studies suggest the existence of a relationship between changes in neurotrophic levels and bipolar disorder (BD). The glial cell-line derived neurotrophic factor (GDNF) influences monoaminergic neurons and glial cells, but its role in BD patients is controversial. In order to elucidate it we evaluated plasma levels of GDNF in a sample of 70 BD patients (35 in mania and 35 in euthymia) and compared with 50 healthy controls matched for age, gender and educational levels. GDNF plasma levels were measured by enzyme-linked immunosorbent assay (ELISA). Patients were assessed by a Mini-International Neuropsychiatric Interview (MINI-plus), Young Mania and Hamilton Depression Rating Scales. Plasma GDNF levels were significantly increased in BD patients in euthymia compared with BD patients in mania and healthy controls (p < 0.05). GDNF plasma levels were correlated with age ( = 0.30, p < 0.05) and negatively correlated with manic symptoms in BD patients ( = −0.54, p < 0.05). Our results provide evidence that peripheral levels of GDNF are related with different mood states in BD, reinforcing the involvement of neurotrophic factors in its physiopathology.
. Post-mortem study of the brain of BD patients demonstrates abnormalities in prefrontal and cingulate grey matter areas mostly characterized by reduced number, density and size of glial population [20] . Dysregulation of neurotrophins imbalance has been suggested as one of the mediators and markers of neuroanatomical brain changes in BD [14] .
Neurotrophins play an important role in synaptic plasticity and have shown to be altered in patients with BD. Brain-derived neurotrophic factor (BDNF) is the most studied neurotrophin in BD. In a recent meta-analysis, Lin [15] showed that levels of BDNF are reduced during mania and depression when compared to healthy controls, but not in euthymic patients. A related neurotrophin that has also been associated with synaptic plasticity is the glial cell-line derived neurotrophic factor (GDNF) [2, 9] . Until now only a few studies have evaluated GDNF levels in BD patients [19, 21, 26, 31] and it is still unclear whether GDNF levels are associated with BD and/or with different mood states.
In order to clarify the role of GDNF in BD, the aims of this study were to evaluate plasma levels of GDNF in a sample of BD patients and to investigate whether mood state (i.e. mania) influences GDNF circulating levels in BD. Seventy BD type I patients (35 in mania and 35 in euthymia) and fifty healthy controls matched for gender, age and years of study were recruited for this study in a public hospital as in-patient or out-patient admission. The control group was recruited from the local population and they did not have any personal or family history of psychiatric disorders, suicide behavior, cognitive deficit or clinical diseases.
All procedures described in this study received approval from the local clinical research ethics committee and are in accordance with the Helsinki Declaration of 1975. Written informed consent was obtained from all patients and healthy subjects prior to conducting any study procedures.
All participants were over the legal age of 18 years old. Subjects with dementia and previous diagnosis of any neurodegenerative disorders, infectious or autoimmune diseases, or who had used corticosteroids, non-steroidal anti-inflammatory drugs or antibiotics 4 weeks before the entry into the study were excluded. As GDNF levels could be influenced by chronic renal failure [18] , no subjects with this condition was included in the study. Psychiatric diagnoses were based on DSM-IV-TR criteria [1] and were performed following a structured clinical interview (Mini-International Neuropsychiatric Interview, MINI-plus) [3, 25] . Healthy controls were assessed by MINI-plus to exclude any psychiatric condition. The severity of manic and depressive symptoms was assessed by the Young Mania Rating Scale (YMRS) [28] and the Hamilton Depression Rating Scale, 17-item version (HDRS) [10] , respectively. Euthymia was defined by YMRS score and HDRS score lower than 7 points for at least four weeks.
All blood samples were drawn at the moment of the clinical assessment. Five milliliters of blood was drawn from each subject by venipuncture into a vacuum tube containing heparin, and was immediately centrifuged twice at 3000 × g for 10 min, and plasma was kept frozen at −70 • C until assayed. Plasma concentration of GDNF was measured according to the procedure provided by the manufacturer using sandwich ELISA kits for GDNF (DuoSet, R&D Systems, Minneapolis, MN, USA). All samples were assayed in duplicate. The detection limits for these assays were 10 pg/mL. Concentration is expressed as pg/mL.
Statistical analyses were performed using SPSS software version 17.0 (SPSS Inc., Chicago, IL, USA). Descriptive statistics were used to report socio-demographic and clinical characteristics of the sample. Association between dichotomous variables was assessed with chi-square test or Fisher's exact test when appropriate. All variables were tested for normality of distribution by means of the Kolmogorov-Smirnov test and all data were non-normally distributed. Two groups (patients vs. controls) were compared by Mann-Whitney test. Differences between three groups (patients in mania vs. patients in euthymia vs. controls) were compared with Kruskal-Wallis test. Multiple comparisons among levels were checked with Dunn's post hoc test. Spearman's correlation analysis was performed to examine the relationship of GDNF levels with age, length of illness, education. All statistical tests were two-tailed and were performed using a significance level of alpha = 0.05.
The demographic and clinical features of all groups are shown in Table 1 . There were no statistical significant differences between BD patients groups and the healthy control group regarding gender, age and years of study. Among BD patients, there were no marked variations among the age of first mood episode, length of disease, number of hospitalizations or medications in use. All patients were medicated.
There was no significant differences in GDNF plasma levels between BD patients and healthy controls (mean ± SD, pg/ml; 55.78 ± 78.42, 39.78 ± 57.89, respectively, p > 0.05) (Fig. 1A) . When comparing BD sub-groups (categorized according to mood state) with healthy controls, GDNF plasma levels were higher in euthymic BD patients in comparison with manic and healthy controls (mean ± SD, pg/ml; euthymia: 76.74 ± 95.26; mania: 34.09 ± 48.80; controls: 40.52 ± 58.99; p < 0.05), post hoc analysis (euthymia vs. mania, p < 0.05; euthymia vs. healthy control, p < 0.05; mania vs. healthy control, p > 0.05) (Fig. 1B) . There was no significant difference between BD patients in mania and controls, but there was a tendency of reduced levels in patients. There was a predominance of female subjects in all groups, but there was no difference in GDNF plasma levels when comparing gender.
GDNF plasma levels were positively correlated with age in BD patients ( = 0.30, p < 0.05); BD patients in euthymia ( = 0.39, p < 0.05); and BD patients in mania ( = 0.47, p < 0.05). GDNF plasma levels were negatively correlated with YMRS in BD patients ( = −0.54, p < 0.05); BD patients in euthymia ( = −0.47, p < 0.05); and BD patients in mania ( = −0.33, p > 0.05). There was no association between GDNF levels and severity of depressive symptoms or duration of illness. Correlation between age and plasma levels of GDNF was not observed in healthy controls.
GDNF levels did not differ in BD categorized according to the presence of clinical comorbities (blood arterial hypertension, diabetes mellitus, dislipidemia, and thyroid diseases), psychiatric comorbities (i.e. generalized anxiety disorder, panic disorder, previously or actual episode of psychosis), dependence of substances (including alcohol and tobacco), previous attempt of suicide and previous depressive episode. Plasma GDNF levels did not differ in BD patients according to the medication in use, such as lithium, anti-convulsants or anti-psychotics (data not show).
In the present study, plasma levels of GDNF were significantly increased in euthymic BD patients in comparison with healthy controls and BD patients in mania. In BD patients, plasma levels of GDNF were negatively correlated with the severity of mania and positively correlated with age. Our results are in line with the hypothesis that altered levels of neurotrophic factors are related with mood changes in BD patients [5, 6, 14, 15, 27] . However it seems that GDNF may present a different balance in comparison with BDNF levels in BD [15] . This is the first study to show higher plasma levels of GDNF in euthymic BD patients in comparison with healthy controls. Otsuki et al. [19] did not find any difference in RNA levels of GDNF when the authors compared BD patients in depression or after their remission and controls. Rosa et al. [21] reported increased serum levels of GDNF in BD patients in depression and mania compared with healthy controls, without difference between euthymic patients and healthy controls. Two studies showed decreased levels of GDNF in BD patients in euthymia [26] and mania or depression [31] . Interestingly, Zhang et al. [31] showed that BD patients evolved with increased serum levels of GDNF after remission of a depression or mania episode.
In the past, the role of GDNF in the development and maintenance of the nigrostriatal system and its relation with dopaminergic system was only implicated in Parkinson's disease physiopathology. Otherwise recent evidence has suggested that the up-regulation of GDNF by astrocytes and microglia may be a protective mechanism to restrain neuronal loss observed in different types of brain diseases [17, 22] . Repeated mood episodes and aging seem to present a cumulative load to BD patients and may be associated with neurotoxicity [13] . Therefore one possible explanation to our results is that mood episodes might be toxic to the brain, reducing GDNF levels. As the person gets older, in order to prevent detrimental effects of mood episodes, GDNF levels would be increased during euthymic states. Reinforcing our results, two previous studies with major depression patients have shown decreased levels of GDNF during acutely ill episode and increased levels of GDNF after mood recovery [29, 30] .
There are some limitations in our study. First, all patients were medicated (mood stabilizing agents, antipsychotics and/or antidepressants) and it is not possible to exclude the effect of drugs in circulating levels of GDNF. Zhang et al. [31] did not find any effect of medication in GDNF levels. Conversely, data from in vitro studies demonstrate increased levels of GDNF in the presence of antidepressants and mood stabilizing agents [4, 8, 11, 24] . Due to the high probability of disease relapse upon drug withdrawal, it is not recommended or ethically acceptable to interrupt drugs in order to rule out the impact of psychotropic drugs in BD patients. Second, it is unknown whether peripheral GDNF levels correlate with GDNF concentration in the central nervous system [12, 16] . The number of subjects included in the present study and the strict inclusion criteria must be considered strengths of our work.
In conclusion, our results are in line with previous studies and suggest the role of neurotrophic factors in BD physiopathology.
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